Picture of DURECT logo

DRRX — DURECT News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapMomentum Trap

Durect Corp Expected To Post A Loss Of 5 Cents A Share: Earnings Preview

* DURECT Corp  DRRX.OQ   DRRX.O  is expected to show a fall
in
quarterly revenue when it reports  results on March 7. 
    * The Cupertino California-based  company is expected to
report  a
4.8% decrease in revenue to $2.1 million from $2.21 million a
year ago, according to the mean estimate from 3 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for DURECT Corp is for
a loss
of 5 cents per share. For the same quarter last year, the
company reported a loss of 4 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for DURECT Corp
is
$6​, about 89.2% above​ its last closing price of $0.65. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.05       -0.05      -0.04     Beat    14.3
 Jun. 30 2021  -0.03       -0.04      -0.04     Met     5.9
 Mar. 31 2021  -0.04       -0.04      -0.05     Missed  -13.6​
 Dec. 31 2020  0.02        -0.03      -0.04     Missed  -26.3
 ​​Sep.        -0.04       -0.04      -0.05     Missed  -15.4
 30 2020                                                
 Jun. 30 2020  0.02        0.02       0.07      Beat    366.7​
 Mar. 31 2020  -0.03       -0.04      -0.05     Missed  -38.9
 Dec. 31 2019  0.00        -0.02      -0.02     Met     -25
 This summary was machine generated March 4 at 23:14 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on DURECT

See all news